Mumbai: Pharma major, Cipla Limited, has announced that it has signed a perpetual license agreement with Novartis Pharma
AG (Switzerland) to manufacture and market Galvus and Galvus combination brands,
used in the treatment of type 2 diabetes from 1st January 2026.
The agreement is subject to satisfaction
of certain conditions precedent, Cipla informed.
“During the interim period we would continue to market and distribute
Galvus branded products. This deal is expected to further bolster Cipla’s position in India as one of the top players in the diabetes category,” the company stated in a recent BSE filing.
Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the
prominent brands in the oral diabetic medication category. Type 2 diabetes stops the body from using insulin properly, which can lead to high levels of blood sugar if not treated.
“Galvus has the potential to contribute
significantly to Cipla’s portfolio in the diabetes care continuum space with reported sales of INR 268 Cr
(IQVIA MAT February 2023),” Cipla further informed.
Medical Dialogues team had earlier reported that Medicines Patent Pool (MPP) had signed sublicence agreements with Aurobindo, Cipla and Viatris – through its subsidiary Mylan – to manufacture generic versions of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).
Cipla Limited is an Indian multinational pharmaceutical and biotechnology company, headquartered in Mumbai, India. The Company was founded by Khwaja Abdul Hamied in 1935 in Mumbai.
The company specializes in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla’s 47 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to 86 markets.Â
Read also: Cipla to sell 51 percent stake in Uganda arm for USD 25-30 million
GIPHY App Key not set. Please check settings